{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:24:03Z","timestamp":1760783043351,"version":"3.35.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,6,13]],"date-time":"2008-06-13T00:00:00Z","timestamp":1213315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmied Arch Pharmacol"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s00210-008-0308-5","type":"journal-article","created":{"date-parts":[[2008,6,12]],"date-time":"2008-06-12T10:08:58Z","timestamp":1213265338000},"page":"515-528","source":"Crossref","is-referenced-by-count":36,"title":["Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15"],"prefix":"10.1007","volume":"378","author":[{"given":"B\u00e9la","family":"Kiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istv\u00e1n","family":"Laszlovszky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"N\u00e9methy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9va","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyula","family":"Bugovics","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K\u00e1roly","family":"Fazekas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istv\u00e1n","family":"Gyerty\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9va","family":"\u00c1gai-Csongor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gy\u00f6rgy","family":"Dom\u00e1ny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Szombathelyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,6,13]]},"reference":[{"key":"308_CR1","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1016\/j.bmcl.2007.08.015","volume":"17","author":"E \u00c1gai-Csongor","year":"2007","unstructured":"\u00c1gai-Csongor E, N\u00f3gr\u00e1di K, Galambos J, V\u00e1g\u00f3 I, Bielik A, Magd\u00f3 I, Ign\u00e1cz-Szendrei G, Keser\u0171 GM, Greiner I, Laszlovszky I, Schmidt E, Kiss B, S\u00e1ghy K, Laszy J, Gyerty\u00e1n I, Zajer-Bal\u00e1zs, G\u00e9mesi L, Dom\u00e1ny G (2007) Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile. Bioorg Med Chem Lett 17:5340\u20135344","journal-title":"Bioorg Med Chem Lett"},{"key":"308_CR2","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1016\/j.bmcl.2007.10.059","volume":"17","author":"J Blagg","year":"2007","unstructured":"Blagg J, Allerton CMN, Batchelor DVJ, Baxter AB, Burring DJ, Carr AS, Nichols CL, Phipps J, Sanderson VG, Verrier H, Wong S (2007) Design and synthesis of functionally selective D3 agonist and its in vivo delivery via intranasal route. Biorg Med Chem Lett 17:6691\u20136696","journal-title":"Biorg Med Chem Lett"},{"key":"308_CR3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00508904","volume":"275","author":"A Carlsson","year":"1972","unstructured":"Carlsson A, Davis JN, Kehr W, Linqduist M, Atack CV (1972) Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo using an inhibitor of the aromatic amino acid decarboxylase. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 275:153\u2013168","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"308_CR4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0014-2999(01)01484-4","volume":"432","author":"MP Castelli","year":"2001","unstructured":"Castelli MP, Mocci I, Sanna AM, Gessa GL, Pani L (2001) (-)S amisulpride bind with high affinity to cloned dopamine D3 and D2 receptors. Eur J Pharmacol 432:143\u2013147","journal-title":"Eur J Pharmacol"},{"key":"308_CR5","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","volume":"22","author":"YC Cheng","year":"1973","unstructured":"Cheng YC, Prusoff WH (1973) Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22:3099\u20133108","journal-title":"Biochem Pharmacol"},{"key":"308_CR6","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s002100000217","volume":"361","author":"D Cussac","year":"2000","unstructured":"Cussac D, Newman-Tancredi A, Sezgin L, Millan MJ (2000) [3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 361:569\u2013571","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"308_CR7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0028-3908(93)90177-5","volume":"32","author":"SA Daly","year":"1993","unstructured":"Daly SA, Waddington JL (1993) Behavioral effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other \u201cD-2 like\u201d agonists. Neuropharmacology 32:509\u2013510","journal-title":"Neuropharmacology"},{"key":"308_CR8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0014-2999(96)00300-7","volume":"308","author":"RR Gainetdinov","year":"1996","unstructured":"Gainetdinov RR, Sotnikova TD, Greghova TV, Rayevsky KG (1996) In vivo evidence for preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. Eur J Pharmacol 308:261\u2013269","journal-title":"Eur J Pharmacol"},{"key":"308_CR9","first-page":"689","volume":"236","author":"MP Galloway","year":"1986","unstructured":"Galloway MP, Wolf ME, Roth RH (1986) Regulation of dopamine synthesis in the medial prefrontal cortex is mediated by release modulating autoreceptors: studies in vivo. J Pharmacol Exp Ther 236:689\u2013698","journal-title":"J Pharmacol Exp Ther"},{"key":"308_CR11","first-page":"899","volume":"275","author":"A Gobert","year":"1995","unstructured":"Gobert A, Rivet J-M, Audinot V, Cistarelli L, Spedding M, Vian J, Peglion J-L, Millan MJ (1995) Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and \u201csilent\u201d D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther 275:899\u2013913","journal-title":"J Pharmacol Exp Ther"},{"key":"308_CR12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/01.fbp.0000137857.26150.ab","volume":"15","author":"I Gyerty\u00e1n","year":"2004","unstructured":"Gyerty\u00e1n I, S\u00e1ghy K (2004) Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U99194A and SB 277011. Behav Pharmacol 15:253\u2013262","journal-title":"Behav Pharmacol"},{"key":"308_CR13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejphar.2007.06.035","volume":"572","author":"I Gyerty\u00e1n","year":"2007","unstructured":"Gyerty\u00e1n I, S\u00e1ghy K (2007) The selective dopamine D3 receptor antagonists, SB 277011-A and S33084 block haloperidol-induced catalepsy in rats. Eur J Pharmacol 572:171\u2013174","journal-title":"Eur J Pharmacol"},{"key":"308_CR14","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/1439-7633(20021004)3:10<946::AID-CBIC946>3.0.CO;2-5","volume":"3","author":"AE Hackling","year":"2002","unstructured":"Hackling AE, Stark H (2002) Dopamine D3 receptor ligands with antagonist properties. ChemBioChem 3:946\u2013961","journal-title":"ChemBioChem"},{"key":"308_CR15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-2999(00)00882-7","volume":"411","author":"CA Heidbreder","year":"2001","unstructured":"Heidbreder CA, Baumann MH (2001) Autoregulation of dopamine synthesis in subregions of the rat nucleus accumbens. Eur J Pharmacol 411:107\u2013113","journal-title":"Eur J Pharmacol"},{"key":"308_CR16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.brainresrev.2004.12.033","volume":"49","author":"CA Heidbreder","year":"2005","unstructured":"Heidbreder CA, Gardner EL, Xi Z-X, Thanos PK, Mugnaini M, Hagan JJ, Ashby CR (2005) The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Rev 49:77\u2013105","journal-title":"Brain Res Rev"},{"key":"308_CR17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0197-0186(00)00047-4","volume":"38","author":"M Hillefors","year":"2001","unstructured":"Hillefors M, von Euler G (2001) Pharmacology of [3H]R(+)-7-OH-DPAT binding in the rat caudate-putamen. Neurochem Int 38:31\u201342","journal-title":"Neurochem Int"},{"key":"308_CR18","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0006-8993(99)01138-5","volume":"822","author":"M Hillefors","year":"1999","unstructured":"Hillefors M, von Euler M, Hedlund PB, von Euler G (1999) prominent binding of the dopamine D3 agonist [3H]PD128907 in the caudate-putamen of the adult rat. Brain Res 822:126\u2013131","journal-title":"Brain Res"},{"key":"308_CR20","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1359-6446(05)03491-4","volume":"10","author":"JN Joyce","year":"2005","unstructured":"Joyce JN, Millan M (2005) Dopamine D3 receptor antagonists as therapeutic agents. Drug Discovery Today 10:917\u2013925","journal-title":"Drug Discovery Today"},{"key":"308_CR21","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","volume":"158","author":"S Kapur","year":"2001","unstructured":"Kapur S, Seeman P (2001) Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 158:360\u2013369","journal-title":"Am J Psychiatry"},{"key":"308_CR22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01281155","volume":"102","author":"T Kling-Petersen","year":"1995","unstructured":"Kling-Petersen T, Ljung E, Svensson K (1995) Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain. J Neural Transm Gen Sect 102:209\u2013220","journal-title":"J Neural Transm Gen Sect"},{"key":"308_CR23","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1523\/JNEUROSCI.18-06-02231.1998","volume":"18","author":"TE Koeltzow","year":"1998","unstructured":"Koeltzow TE, Xu M, Cooper DC, Tonegawa S, Wolf ME, White FJ (1998) Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. J Neurosci 18:2231\u20132238","journal-title":"J Neurosci"},{"key":"308_CR24","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/0006-2952(85)90778-6","volume":"34","author":"C K\u00f6hler","year":"1985","unstructured":"K\u00f6hler C, Hall H, \u00d6gren S-O, Gawell L (1985) Specific in vitro and in vivo binding of 3H-raclopride a potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34:2251\u20132259","journal-title":"Biochem Pharmacol"},{"key":"308_CR25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/sj.npp.1300114","volume":"28","author":"LP Lacroix","year":"2003","unstructured":"Lacroix LP, Hows MEP, Shah AJ, Hagan J, Heidbreder CA (2003) Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology 28:839\u2013849","journal-title":"Neuropsychopharmacology"},{"key":"308_CR26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jneumeth.2006.03.017","volume":"157","author":"LP Lacroix","year":"2006","unstructured":"Lacroix LP, Ceolin L, Zocchi A, Varnier G, Garzotti M, Curcuruto O, Heidbreder CA (2006) Dopamine D3 antagonists enhance cortical acetylcholine levels measured with high-performance chromatography\/tandem mass spectrometry without anti-cholinesterases. J Neurosci Methods 157:25\u201331","journal-title":"J Neurosci Methods"},{"key":"308_CR27","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00213-004-2096-z","volume":"179","author":"J Laszy","year":"2005","unstructured":"Laszy J, Laszlovszky I, Gyerty\u00e1n I (2005) Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berl) 179:567\u2013575","journal-title":"Psychopharmacology (Berl)"},{"key":"308_CR28","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1021\/jm020952a","volume":"45","author":"M Leopoldo","year":"2002","unstructured":"Leopoldo M, Berardi F, Colabufo NA, De Giorgio P, Lacivita E, Perrone R, Tortorella V (2002) Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective D3 receptor ligands. J Med Chem 45:5727\u20135735","journal-title":"J Med Chem"},{"key":"308_CR29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0031-6997(24)01327-9","volume":"49","author":"B Levant","year":"1997","unstructured":"Levant B (1997) The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 49:231\u2013252","journal-title":"Pharmacol Rev"},{"key":"308_CR30","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1016\/S0014-2999(97)00049-6","volume":"321","author":"MJ Millan","year":"1997","unstructured":"Millan MJ, Gressier H, Brocco M (1997) The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Eur J Pharmacol 321:R7\u2013R9","journal-title":"Eur J Pharmacol"},{"key":"308_CR31","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0022-3565(24)39332-2","volume":"293","author":"MJ Millan","year":"2000","unstructured":"Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet J-M, Audinot V, Dubuffet T, Lavielle G (2000) S33084 a novel, potent, selective and competitive antagonist at dopamine D3 receptors: I Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 293:1048\u20131062","journal-title":"J Pharmacol Exp Ther"},{"key":"308_CR32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00213-003-1770-x","volume":"174","author":"MJ Millan","year":"2004","unstructured":"Millan MJ, Seguin L, Gobert A, Cussac D, Brocco M (2004) The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology (Berl) 174:341\u2013357","journal-title":"Psychopharmacology (Berl)"},{"key":"308_CR33","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1471-4159.2006.04262.x","volume":"100","author":"MJ Millan","year":"2007","unstructured":"Millan MJ, Di Cara B, Dekeyne A, Panayi F, De Groote L, Sicard D, Cistarelli L, Billiras R, Gobert A (2007) Selective blockade of dopamine D3 versus D2 receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioral analysis. J Neurochem 100:1047\u20131061","journal-title":"J Neurochem"},{"key":"308_CR34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","volume":"78","author":"C Missale","year":"1998","unstructured":"Missale C, Nash R, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189\u2013225","journal-title":"Physiol Rev"},{"key":"308_CR35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1192\/S0007125000298309","volume":"168","author":"S Nyberg","year":"1996","unstructured":"Nyberg S, Nakashima Y, Nordstr\u00f6m A-L, Halldin C, Farde L (1996) Positron emission tomography of in vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response. Br J Psychiatry 168:40\u201344","journal-title":"Br J Psychiatry"},{"key":"308_CR36","first-page":"158","volume":"264","author":"M Oka","year":"1992","unstructured":"Oka M, Noda Y, Ochi Y, Furukawa K, Une T, Kurumiya S, Hino K, Karasawa T (1992) Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther 264:158\u2013165","journal-title":"J Pharmacol Exp Ther"},{"key":"308_CR37","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/22560","volume":"400","author":"M Pilla","year":"1999","unstructured":"Pilla M, Perachon S, Sautel F, Garrido F, Manni A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P (1999) Selective inhibition of cocaine seeking behavior by partial dopamine D3 receptor agonist. Nature 400:371\u2013375","journal-title":"Nature"},{"key":"308_CR38","first-page":"1355","volume":"275","author":"TA Pugsley","year":"1995","unstructured":"Pugsley TA, Davis MD, Akunne HC, Mackenzie RG, Shih YH, Damsma G, Wikstrom H, Whetzel SZ, Georgic LM, Cooke LW, Demattos SB, Corbin AE, Glase SA, Wise LD, Dijkstra D, Heffner TG (1995) Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther 275:1355\u20131366","journal-title":"J Pharmacol Exp Ther"},{"key":"308_CR39","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S0022-3565(24)39184-0","volume":"294","author":"C Reavill","year":"2000","unstructured":"Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, Hadley MS, Hunter AJ, Jeffrey P, Jewitt F, Johnson CN, Jones DN, Meadhearst AD, Middlemiss DN, Nash DJ, Riley GJ, Routledge C, Stemp G, Thewlis KM, Trainl B, Vong AK, Hagan JJ (2000) Pharmacological actions of a novel, high affinity, and selective human D3 receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294:1154\u20131165","journal-title":"J Pharmacol Exp Ther"},{"key":"308_CR40","first-page":"6","volume":"340","author":"SB Ross","year":"1989","unstructured":"Ross SB, Jackson DM (1989) Kinetic properties of the accumulation of [3H]raclopride in the mouse brain in vivo. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 340:6\u201312","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"308_CR41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","volume":"283","author":"H Schoemaker","year":"1997","unstructured":"Schoemaker H, Claustre Y, Fage D, Rouquier DFL, Chergui K, Curet O, Oblin A, Carter C, Benavides J, Scatton B (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 283:83\u201397","journal-title":"J Pharmacol Exp Ther"},{"key":"308_CR42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0014-2999(92)90196-B","volume":"218","author":"A Schotte","year":"1992","unstructured":"Schotte A, Janssen PFM, Gommeren W, Luyten WHLM, Leysen J (1992) Autoradiographic evidence for the occlusion of rat brain dopamine D3 receptors in vivo. Eur J Pharmacol 218:373\u2013375","journal-title":"Eur J Pharmacol"},{"key":"308_CR43","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0165-0173(99)00043-0","volume":"31","author":"J-C Schwartz","year":"2000","unstructured":"Schwartz J-C, Diaz J, Pilon C, Sokoloff P (2000) Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions. Brain Res Rev 31:277\u2013287","journal-title":"Brain Res Rev"},{"key":"308_CR44","first-page":"591","volume-title":"Methods in biogenic amine research","author":"P Seeman","year":"1983","unstructured":"Seeman P (1983) Dopamine receptor measurement with [3H]ligands. In: Parvez S, Nagatsu T, Nagatsu I, Parvez H (eds) Methods in biogenic amine research. Elsevier, Amsterdam, pp 591\u2013622"},{"key":"308_CR45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1566-2772(00)00007-4","volume":"1","author":"P Seeman","year":"2001","unstructured":"Seeman P (2001) Antipsychotic drugs, dopamine receptors and schizophrenia. Clin Neurosci Res 1:53\u201360","journal-title":"Clin Neurosci Res"},{"key":"308_CR46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-2999(97)01235-1","volume":"336","author":"S Sigala","year":"1997","unstructured":"Sigala S, Missale C, Spano P (1997) Opposite effects of dopamine D2 and D3 receptors on learning and memory in the rat. Eur J Pharmacol 336:107\u2013112","journal-title":"Eur J Pharmacol"},{"key":"308_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002130050479","volume":"135","author":"R Shafer","year":"1998","unstructured":"Shafer R, Levant B (1998) The D3 dopamine receptor in cellular and organismal function. Psychopharmacology 135:1\u201316","journal-title":"Psychopharmacology"},{"key":"308_CR49","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/347146a0","volume":"347","author":"P Sokoloff","year":"1990","unstructured":"Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz J-C (1990) Molecular cloning and characterisation of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146\u2013151","journal-title":"Nature"},{"key":"308_CR50","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1749-6632.1995.tb17486.x","volume":"757","author":"P Sokoloff","year":"1995","unstructured":"Sokoloff P, Diaz J, Levesque D, Pilon C, Dimitriadou V, Griffon N, Lammers CH, Martres MP, Schwartz J-C (1995) Novel dopamine receptor subtypes as targets for antipsychotic drugs. Ann NY Acad Sci USA 757:278\u2013292","journal-title":"Ann NY Acad Sci USA"},{"key":"308_CR51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/187152706784111551","volume":"5","author":"P Sokoloff","year":"2006","unstructured":"Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C (2006) The dopamine D3 receptor: A therapeutic target for the treatment of neuropsychiatric disorders. CNS & Neurological Disorder\u2013Drug Targets 5:25\u201343","journal-title":"CNS & Neurological Disorder\u2013Drug Targets"},{"key":"308_CR52","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11920-007-0041-7","volume":"9","author":"M Toda","year":"2007","unstructured":"Toda M, Abi-Dargham A (2007) Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiat Rep 9:329\u2013336","journal-title":"Curr Psychiat Rep"},{"key":"308_CR53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF00498834","volume":"296","author":"JR Walters","year":"1976","unstructured":"Walters JR, Roth RH (1976) Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors. Naunyn Schmiedeberg\u2019s Arch Pharmacol 296:5\u201314","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"308_CR54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF01244979","volume":"94","author":"N Waters","year":"1993","unstructured":"Waters N, Svensson K, Haadsma-Svensson SR, Smith MW, Carlsson A (1993) The dopamine D3 receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm Gen Sect 94:11\u201319","journal-title":"J Neural Transm Gen Sect"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-008-0308-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-008-0308-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-008-0308-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T17:47:16Z","timestamp":1738259236000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-008-0308-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,13]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["308"],"URL":"https:\/\/doi.org\/10.1007\/s00210-008-0308-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"type":"print","value":"0028-1298"},{"type":"electronic","value":"1432-1912"}],"subject":[],"published":{"date-parts":[[2008,6,13]]}}}